文章摘要

大剂量氨溴索联合左氧氟沙星治疗老年慢性阻塞性肺疾病伴重症肺炎患者的临床效果

作者: 1任佳荣, 1任登华
1 无锡市锡山人民医院呼吸内科,江苏 无锡 214000
通讯: 任佳荣 Email: 626648492@qq.com
DOI: 10.3978/j.issn.2095-6959.2020.10.011

摘要

目的:研究老年慢性阻塞性肺疾病伴重症肺炎患者采用大剂量氨溴索联合左氧氟沙星治疗的效果及安全性。方法:选取2016年6月至2019年6月期间100例慢性阻塞性肺疾病伴重症肺炎老年患者,随机分为观察组与对照组,各50例。两组患者均给予左氧氟沙星治疗,在此基础上,对照组给予常规剂量氨溴索治疗,观察组给予大剂量氨溴索治疗,对比两组治疗效果。结果:治疗后,观察组用力肺活量(FVC)、第1秒用力呼气容积(FEV1)等肺功能指标水平高于对照组(P<0.05);观察组肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)等炎症指标水平低于对照组(P<0.05);氧化应激指标水平方面,观察组SOD水平高于对照组,MDA水平低于对照组(P<0.05);用药不良反应方面,两组无明显差异(P>0.05)。结论:对老年慢性阻塞性肺疾病伴重症肺炎患者采用大剂量氨溴索联合左氧氟沙星治疗,可显著改善患者肺功能,有效缓解患者机体炎性水平,改善患者氧化应激水平,用药安全性高,疗效可靠,值得推广。
关键词: 老年慢性阻塞性肺疾病;重症肺炎;大剂量;氨溴索;左氧氟沙星;不良反应

Clinical effect of high-dose ambroxol combined with levofloxacin in elderly chronic obstructive pulmonary disease patients with severe pneumonia

Authors: 1REN Jiarong, 1REN Denghua
1 Wuxi Xishan people's Hospital Respiratory Medicine, Wuxi Jiangsu 214000, China

CorrespondingAuthor: REN Jiarong Email: 626648492@qq.com

Abstract

Objective: To study the efficacy and safety of high-dose ambroxol combined with levofloxacin in elderly chronic obstructive pulmonary disease (COPD) patients with severe pneumonia. Methods: A total of 100 elderly patients with COPD with severe pneumonia from June 2016 to June 2019 were selected and randomly divided into an observation group and a control group, each with 50 cases. Both groups of patients were treated with levofloxacin. Based on this, the control group was given a conventional dose of ambroxol, and the observation group was given a large dose of ambroxol. The treatment effects were compared between the 2 groups. Results: After the treatment, the levels of lung function indicators such as FVC and FEV1 in the observation group were higher than those in the control group (P<0.05); the levels of inflammation indicators such as TNF-α and CRP in the observation group were lower than those in the control group (P<0.05); oxidative stress indicators In terms of levels, the SOD level in the observation group was higher than that in the control group, and the MDA level was lower than in the control group (P<0.05). There were no significant differences in the adverse reactions between the two groups (P>0.05). Conclusion: The use of high-dose ambroxol combined with levofloxacin in elderly patients with chronic obstructive pulmonary disease with severe pneumonia can significantly improve the pulmonary function of patients, effectively relieve the patient's inflammatory level, improve the patient's oxidative stress level, and have high drug safety , the effect is reliable and worthy of promotion.
Keywords: chronic obstructive pulmonary disease in the elderly; severe pneumonia; high dose; ambroxol; levofloxacin; adverse reactions